GNW-Adhoc: Biognosys presents technological innovations and scientific advances related to the use of the proteome for life science…

^* Library-free and machine learning-powered data analysis

with Spectronaut(®) 18 enables an industry-leading

Protein quantification and high throughput for DIA proteomics

* New joint research with the service platforms TrueDiscovery(®) and

TrueTarget(®) for contract research organizations demonstrates the quantitative

Precision and broad applicability of mass spectrometry proteomics for the

Biomarker discovery and drug development

* Biognosys’ iRT kit is the cornerstone of novel real-time

Performance monitoring from Bruker as part of ProteoScape(TM) analysis for

timsTOF instruments

ZURICH, Switzerland, and CAMBRIDGE, Massachusetts, Sept. 17, 2023 (GLOBE NEWSWIRE)

— Biognosys, a leading inventor and developer of mass spectrometry

(MS)-based proteomics solutions, today announced its participation in the World Congress

Human Proteome Organization (HUPO) from September 17th to 21st

(https://2023.hupo.org/) in Busan, South Korea.

During the Technological Advances session on Tuesday, September 19,

will Dr. Lukas Reiter, Chief Technology Officer of Biognosys, a keynote speech

Presentation entitled “Bottom-up Proteomics using DIA”.

with DIA) about the development, recent developments and the future of the

data-independent acquisition (DIA) in the MS

based proteomics. Biognosys will also present ten posters,

the technological innovations and new scientific data with its

introduce proprietary proteomics research services, software and kits.

Biognosys’ scientific expert team will be at booth #408

exhibit and offer software demonstrations.

Biognosys’ strategic partner, Bruker, will develop new concepts for the

Introduce the timsTOF platform and the Bruker ProteoScape(TM) software suite and

Synergies with Biognosys’ Spectronaut(®) software and iRT kit

to provide customers with expanded options for high-fidelity proteomics

with high throughput.

“I am excited that we have MS proteomics technology and solutions

Biognosys has been able to make significant progress that brings us closer again

to use the proteome for research, drug development and

to truly harness clinical decision-making,” commented Dr.

Lukas Reiter.?Our constantly improved software and our proven kits

enable users of key MS instruments to have state-of-the-art,

Hassle-free workflows for deep, reproducible proteomics research

to be carried out in-house. Our services for contract research organizations

offer our customers in the biopharma and diagnostics industry unparalleled

Precision and insights to drive biomarker discovery and development

of medication.”

Spectronaut(®) 18: Industry-leading depth, throughput and efficiency for DIA

Data analysis

Spectronaut 18, the latest version of Biognosys’ flagship product, offers a

Significantly further improved identification rate and quantification quality

as well as various new features that make DIA proteomics more efficient and

make it more scalable. Biognosys will present three posters at the HUPO congress

present the powerful applications of the Spectronaut 18 for the

present comprehensive quantification of proteomes. Among the notable ones

Innovations include the use of directDIA+(TM) for faster,

Library-free analysis and deep learning with DeepQuant to improve

Quantification of low-abundance proteins by a neuronal

Precursor set interference correction network.

TrueDiscovery(®): Proven precision for biomarker discovery in oncology

and neuroscience

Biognosys will present three posters detailing the research leading to the discovery

of biomarkers and the development of drugs is presented in

Collaboration with respected partners such as Genmab, Johns Hopkins University

School of Medicine, Stanford University and the University of Zurich

was carried out. The studies used the TrueDiscovery platform

Biognosys for unbiased proteomics and demonstrate overall quantitative

Precision, robustness and broad applicability of MS proteomics for the

oncological and neuroscientific research. A fourth poster rated

the technological and biological complementarity of TrueDiscovery and the

affinity-based platform Olink(®) Explore from Olink Proteomics AB for

Plasma proteomics.

TrueTarget(®): Efficient target unfolding and mapping of binding sites in

drug research

Biognosys’ TrueTarget platform leverages mass spectrometry

limited proteolysis (LiP-MS) to identify and validate

To facilitate drug targets. A first poster created in collaboration with

InterAx was created, demonstrating the unique capabilities of

TrueTarget in decoding the target of a G-protein-coupled

receptor (GPCR) antagonists, the mapping of its binding sites and the

Providing structural insights into the mechanism of action. A second

Poster, created in collaboration with Samsara Therapeutics, shows how the

Deconvolution of target proteins with TrueTarget and the subsequent

unbiased proteome profiling with TrueDiscovery

efficient identification and validation of target proteins and a better

Understanding biological systems enables the development of new therapies.

Biognosys and Bruker: Seamless workflows for dia-PASEF(®) and QC

timsTOF

To ensure optimal MS performance, Bruker introduces TwinScape(TM),

a digital twin for the timsTOF platform that works with the ProteoScape

Software is connected to real-time quality control (QC).

Biognosys iRT kit to support. The peptides in the iRT kit were carefully selected

Stability, sensitivity and retention time intervals optimized. This

iRT kit can now be used for system QC in ProteoScape proteomics software

Bruker can be used. Dr. Sira Echevarria, Head of Business Development –

Products at Biognosys, will be presented during Bruker’s HUPO lunch seminar on

Tuesday, September 19th, present how Spectronaut an improved

offers library-free proteome analysis for dia-PASEF with directDIA+.

Visit biognosys.com/hupo-2023 (https://biognosys.com/hupo-2023/) for

a complete overview of Biognosys’ presence at the congress

the HUPO. The posters will be available for download from Friday, September 22nd.

About Spectronaut(®)

Spectronaut is Biognosys’ flagship in the field of data analysis for

the data-independent acquisition in mass spectrometry-based proteomics.

The software uses advanced algorithms for search and artificial

Intelligence (AI) to transform data into actionable insights for the

transforming life science research. Spectronaut makes this possible

reproducible and precise quantification of thousands of proteins in one

single experiment and offers multidimensional insights into protein expression,

-function and structure in all major biological species and

Sample types. For more information, visit spectronaut.com

(http://spectronaut.com/).

About TrueDiscovery(®)

Biognosys’ TrueDiscovery platform provides integrated proteomics solutions

for the entire drug development.

TrueDiscovery is based on Hyper Reaction Monitoring (HRM)

Mass spectrometry, an advanced technology co-invented by Biognosys

patented technology for the quantification of proteins based on

independent data acquisition (Data Independent Acquisition; DIA).

TrueDiscovery is the only platform that searches the entire proteome to

Thousands of the most important proteins, including an unlimited number of

Proteoforms to quantify. The platform enables the most profound,

unadulterated profiling of tissue and biofluid proteomes with

unbeatable specificity at scale. The data generated is high

Measurements reproducible and easily transferable to clinical testing. The studies

can be carried out in a GLP-certified and GCP-compliant environment

become. For more information, visit truediscovery.bio

(http://truediscovery.bio/).

About TrueTarget(®)

Biognosys’ TrueTarget proteomics platform is a unique solution for

the most pressing challenges in early drug development by

They identify on- and off-targets to facilitate drug development in the

accelerate the entire pipeline and reduce risk.

TrueTarget is based on Limited Proteolysis Mass Spectrometry (LiP-MS), a

patented chemoproteomics technology co-developed by Biognosys.

TrueTarget is the only tool that detects structural changes throughout

Proteome studied at peptide level resolution making it unique

Insights into the binding of substances and the identification of targets

enabled.

The platform enables mechanisms of action to be clarified and uncovered

of unexpected toxicities. For more information, see

truetarget.bio (http://truetarget.bio/)

About Biognosys

At Biognosys, we believe that deep insights into the proteome are the key

groundbreaking discoveries that are changing science and life

improve. With our diverse portfolio of proteomics solutions

next generation, including research service platforms

TrueDiscovery(®), TrueTarget(®) and TrueSignature(®), our flagship

Software Spectronaut(®) and the PQ500(TM) kit, we make the proteome

capable of conducting research, drug development and clinical

to support decisions. Our solutions offer a multidimensional

View of protein expression, function and structure in all biological

Species and sample types. Use our unique, patented technologies

using high-resolution mass spectrometry to identify thousands of proteins

quantify depth and throughput with industry-leading precision. Through ours

Strategic partnership with Bruker (Nasdaq: BRKR) we do proteomics

accessible worldwide. For more information, visit biognosys.com

(http://www.biognosys.com/).

The source language in which the original text is published is

official and authorized version. Translations are becoming better

Communication included. Only the language version, the original

published is legally valid. Therefore, compare translations

the original language version of the publication.

°

ttn-28